On March 15, 2012, Lin, Hong; Erhard, Karl; Hardwicke, Mary Ann; Luengo, Juan I.; Mack, James F.; McSurdy-Freed, Jeanelle; Plant, Ramona; Raha, Kaushik; Rominger, Cynthia M.; Sanchez, Robert M.; Schaber, Michael D.; Schulz, Mark J.; Spengler, Michael D.; Tedesco, Rosanna; Xie, Ren; Zeng, Jin J.; Rivero, Ralph A. published an article.Quality Control of 7-Chloroimidazo[1,2-a]pyrimidin-5(1H)-one The title of the article was Synthesis and structure-activity relationships of imidazo[1,2-a]pyrimidin-5(1H)-ones as a novel series of beta isoform selective phosphatidylinositol 3-kinase inhibitors. And the article contained the following:
A series of PI3K-beta selective inhibitors, imidazo[1,2-a]-pyrimidin-5(1H)-ones, has been rationally designed based on the docking model of the more potent R enantiomer of TGX-221, identified by a chiral separation, in a PI3K-beta homol. model. Synthesis and SAR of this novel chemotype are described. Several compounds in the series demonstrated potent growth inhibition in a PTEN-deficient breast cancer cell line MDA-MB-468 under anchorage independent conditions. The experimental process involved the reaction of 7-Chloroimidazo[1,2-a]pyrimidin-5(1H)-one(cas: 57473-33-3).Quality Control of 7-Chloroimidazo[1,2-a]pyrimidin-5(1H)-one
The Article related to phosphatidylinositol kinase isoform inhibitor imidazopyrimidinone preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Quality Control of 7-Chloroimidazo[1,2-a]pyrimidin-5(1H)-one
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem